121 related articles for article (PubMed ID: 24238760)
21. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.
Wissing MD; van Oort IM; Gerritsen WR; van den Eertwegh AJ; Coenen JL; Bergman AM; Gelderblom H
Clin Genitourin Cancer; 2013 Sep; 11(3):238-250.e1. PubMed ID: 23659772
[TBL] [Abstract][Full Text] [Related]
22. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
[TBL] [Abstract][Full Text] [Related]
23. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Dueck G; Chua N; Prasad A; Finch D; Stewart D; White D; van der Jagt R; Johnston J; Belch A; Reiman T
Cancer; 2010 Oct; 116(19):4541-8. PubMed ID: 20572046
[TBL] [Abstract][Full Text] [Related]
24. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Rothermundt C; Hayoz S; Templeton AJ; Winterhalder R; Strebel RT; Bärtschi D; Pollak M; Lui L; Endt K; Schiess R; Rüschoff JH; Cathomas R; Gillessen S
Eur Urol; 2014 Sep; 66(3):468-74. PubMed ID: 24412228
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
Zhang MM; Chan JK; Husain A; Guo HY; Teng NN
Gynecol Oncol; 2007 Apr; 105(1):194-8. PubMed ID: 17257661
[TBL] [Abstract][Full Text] [Related]
26. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
Sonpavde G; Aparicio AM; Zhan F; North B; Delaune R; Garbo LE; Rousey SR; Weinstein RE; Xiao L; Boehm KA; Asmar L; Fleming MT; Galsky MD; Berry WR; Von Hoff DD
Urol Oncol; 2011; 29(6):682-9. PubMed ID: 19959380
[TBL] [Abstract][Full Text] [Related]
27. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
28. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer.
Chadha MK; Ashraf U; Lawrence D; Tian L; Levine E; Silliman C; Escott P; Payne V; Trump DL
Prostate; 2008 Sep; 68(13):1461-6. PubMed ID: 18618738
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN
Clin Genitourin Cancer; 2015 Apr; 13(2):124-9. PubMed ID: 24993934
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
33. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
[TBL] [Abstract][Full Text] [Related]
34. Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer.
Turo R; Tan K; Thygesen H; Sundaram SK; Chahal R; Prescott S; Cross WR
Urol Int; 2015; 94(3):307-12. PubMed ID: 25342383
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
Moore MM; Stockler M; Lim R; Mok TS; Millward M; Boyer MJ
Cancer Chemother Pharmacol; 2010 Oct; 66(5):845-50. PubMed ID: 20082080
[TBL] [Abstract][Full Text] [Related]
36. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
Hervonen P; Tulijoki T; Kellokumpu-Lehtinen P
Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906
[TBL] [Abstract][Full Text] [Related]
37. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
38. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Mathew P; Tannir N; Tu SM; Carter CM; Bekele NB; Pagliaro L
Cancer Chemother Pharmacol; 2010 Mar; 65(4):811-5. PubMed ID: 20052472
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.
Wang J; McGuire TR; Britton HC; Schwarz JK; Loberiza FR; Meza JL; Talmadge JE
Clin Exp Metastasis; 2015 Feb; 32(2):111-24. PubMed ID: 25617965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
